Cyclopharm’s Technegas Gains CMS Reimbursement Status

Cyclopharm Limited (AU:CYC) has released an update.

Cyclopharm Limited has announced that its radiopharmaceutical product, Technegas, has been granted Pass-Through reimbursement status by the Centre for Medicare and Medicaid Services (CMS) starting July 1, 2024, ensuring full reimbursement for the product in the US. This key financial development, paired with a unique identification code for streamlined processing, is expected to expedite the deployment of Technegas across the United States. CEO James McBrayer expressed optimism about the CMS decision’s timing, coinciding with Cyclopharm’s significant presence at an upcoming major nuclear medicine conference.

For further insights into AU:CYC stock, check out TipRanks’ Stock Analysis page.